Back to top
more

Pluristem Therapeutics, Inc. (PSTI)

(Delayed Data from NSDQ)

$0.65 USD

0.65
294,580

+0.01 (1.27%)

Updated May 3, 2019 04:13 PM ET

After-Market: $0.65 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Brokerage Reports

0 items in cart

Pluri Inc. [PSTI]

Reports for Purchase

Showing records 1 - 20 ( 82 total )

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

07/15/2022

Daily Note

Pages: 4

Encouraging Initial Data from HIPGEN Study; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

07/13/2022

Company Report

Pages: 5

Lowering to Neutral from BUY as Pluristem Hip Trial Misses the Primary Endpoint

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

05/10/2022

Company Report

Pages: 5

BUY: Reports 3Q22 - $61M in Cash & Equivalents

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 5.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

02/24/2022

Company Report

Pages: 6

BUY: The Deal is On - Food Company Tnuva is In for a Bite

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/10/2022

Company Report

Pages: 6

BUY: Food Company Tnuva Invests $7.5M for R&D Service

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/01/2021

Company Report

Pages: 6

BUY: Swinging Hips - PLX-PAD Pivotal Trial Fully Enrolled-

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

12/01/2021

Company Report

Pages: 6

BUY: Swinging Hips - PLX-PAD Pivotal Trial Fully Enrolled

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 12.50

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for PSTI

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

07/08/2021

Company Report

Pages: 5

Is There a Signal in ARDS? Pluristem will Analyze the Current Data Sets

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

05/10/2021

Company Report

Pages: 7

PLX-R18 Shows Potential in Hematological Indication; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/04/2021

Company Report

Pages: 5

BUY: Phase 1 Study Shows Promise in HCT

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

02/16/2021

Company Report

Pages: 7

Catalyst-Rich 2021 Expected; Higher $10 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

12/10/2020

Company Report

Pages: 6

Opportunities Beyond CLI Remain Intact; Lower PT to $9; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

12/09/2020

Company Report

Pages: 7

BUY: CLI Study is Halted as Low Event Rate in Control Diminutive to the Study?s Power

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

12/07/2020

Company Report

Pages: 7

Positive PLX-R18 Data at ASH; CLI Phase 3 Interim Data Imminent; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

10/07/2020

Company Report

Pages: 5

BUY: China Virus Trial Expands to Israel

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/15/2020

Company Report

Pages: 5

BUY: A Pivotal Year

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

08/27/2020

Company Report

Pages: 5

BUY- COVID-19 - ARDS Expanded Access Granted

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 10.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/10/2020

Company Report

Pages: 7

BUY: COVID-19 - ARDS Trial Expands to Europe

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Pluri Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

06/11/2020

Company Report

Pages: 7

BUY: The U.S. Phase 2 Trial in COVID-19 ? ARDS Begins

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

// eof